Summit Therapeutics Inc.

Good morning and welcome to the Summit Therapeutics third quarter 2023 earnings and update call. All participants will be able to listen only until the question and answer portion of this call. We do not expect any technical difficulties today. However, in the event that we lose the webcast connection and we are unable to provide any updates, please wait up to 10 minutes for resolution. Please refer to the company's website for updates. Please note that today's call is being recorded. To ask a question, simply press star, followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press star one. At this time, I would like to introduce the call to Dave Jankars, Chief Business and Strategy Officer. You may proceed.

And thank you for joining us. Our press release was issued earlier this morning and is available on the homepage of our website. Our Form 10-Q was also filed earlier this morning and is available on our website. Today's call is being simultaneously webcast and an archived replay will be available later today on our website, www.smmtx.com. Joining me on the call today is Bob Duggan, our Chairman of the Board and Chief Executive Officer. Dr. Maki Zangane, our Chief Executive Officer and President. Ankur Dhingra, our Chief Financial Officer. Dr. Alan Yang, our Chief Medical Officer. And in addition, we are joined by our new Chief Operating Officer, Manmeet Soni. Manmeet joins us from Reata Pharmaceuticals, where he was the President, Chief Operating Officer, and Chief Financial Officer. Reata was recently purchased by Biogen for approximately $7.5 billion. Manmeet was previously the CFO at Alnylon Pharmaceuticals and Ariat Pharmaceuticals. Before that, he was the CFO of Pharmacyclics. Manmeet will continue to serve on our board, and he also serves on the board of Pulse Biosciences. Manmeet will be responsible for all commercial activities, finance, clinical operations, manufacturing, legal, information technology, and human resources. In conjunction with Manmeet joining us, he invested $5 million in the company and a private placement at Market Race. We are excited to have Manmeet join Team Summit, and I'd like to welcome Manmeet to the team.

Thanks, Dave, and I'm very excited to be here and be part of Team Summit. I worked with the team here at Summit for the last four years as a board member, and I'm very thrilled to join as a member of the very accomplished and committed management team. I strongly believe that our pipeline candidate, Ivonisimab, with two phase three clinical trials, currently enrolling in the United States, Canada, Europe, and China, has the potential to bring a paradigm shift in the standard of care for patients with solid tumors, starting with non-small cell lung cancer. I'm fully committed to our mission of developing new, innovative, and patient-friendly medicines for unmet medical needs. And I'm excited to contribute to making this positive, meaningful difference.